| review article | Q7318358 |
| scholarly article | Q13442814 |
| P2093 | author name string | Neel BG | |
| Barford D | |||
| P2860 | cites work | Spatial constraints on the recognition of phosphoproteins by the tandem SH2 domains of the phosphatase SH-PTP2 | Q24314461 |
| Differential functions of the two Src homology 2 domains in protein tyrosine phosphatase SH-PTP1 | Q24319091 | ||
| MOLSCRIPT: a program to produce both detailed and schematic plots of protein structures | Q26778412 | ||
| Crystal structures of peptide complexes of the amino-terminal SH2 domain of the Syp tyrosine phosphatase | Q27729401 | ||
| Structural basis for phosphotyrosine peptide recognition by protein tyrosine phosphatase 1B | Q27729426 | ||
| Crystal structure of Yersinia protein tyrosine phosphatase at 2.5 A and the complex with tungstate | Q27730850 | ||
| Crystal structure of human protein tyrosine phosphatase 1B | Q27731235 | ||
| Structural basis for inhibition of receptor protein-tyrosine phosphatase-alpha by dimerization | Q27733166 | ||
| Three-dimensional structure of the tyrosine kinase c-Src | Q27734749 | ||
| Crystal structure of the Src family tyrosine kinase Hck | Q27734750 | ||
| The crystal structure of domain 1 of receptor protein-tyrosine phosphatase mu | Q27746489 | ||
| Crystal structure of the tyrosine phosphatase SHP-2 | Q27748898 | ||
| Protein modules and signalling networks | Q27860694 | ||
| Signaling through scaffold, anchoring, and adaptor proteins | Q28131792 | ||
| The nonreceptor protein tyrosine phosphatase corkscrew functions in multiple receptor tyrosine kinase pathways in Drosophila | Q28298747 | ||
| Activation of the Src-family tyrosine kinase Hck by SH3 domain displacement | Q30014848 | ||
| Modular peptide recognition domains in eukaryotic signaling | Q30176687 | ||
| Abnormal mesoderm patterning in mouse embryos mutant for the SH2 tyrosine phosphatase Shp-2. | Q33886525 | ||
| Protein tyrosine phosphatases in signal transduction. | Q34419522 | ||
| Overexpression, purification, and characterization of SHPTP1, a Src homology 2-containing protein-tyrosine-phosphatase | Q36089596 | ||
| Structural determinants of SHP-2 function and specificity in Xenopus mesoderm induction | Q39631199 | ||
| corkscrew encodes a putative protein tyrosine phosphatase that functions to transduce the terminal signal from the receptor tyrosine kinase torso | Q42612628 | ||
| Ligand-mediated negative regulation of a chimeric transmembrane receptor tyrosine phosphatase | Q46161173 | ||
| Potent stimulation of SH-PTP2 phosphatase activity by simultaneous occupancy of both SH2 domains | Q71673010 | ||
| Regulation of protein tyrosine phosphatase 1C: opposing effects of the two src homology 2 domains | Q71682548 | ||
| The SH2-containing protein-tyrosine phosphatase SH-PTP2 is required upstream of MAP kinase for early Xenopus development | Q72553432 | ||
| Tandem SH2 domains confer high specificity in tyrosine kinase signaling | Q74016240 | ||
| P433 | issue | 3 | |
| P304 | page(s) | 249-254 | |
| P577 | publication date | 1998-03-01 | |
| P1433 | published in | Structure | Q15709970 |
| P1476 | title | Revealing mechanisms for SH2 domain mediated regulation of the protein tyrosine phosphatase SHP-2. | |
| P478 | volume | 6 |
| Q33961297 | Activated mutants of SHP-2 preferentially induce elongation of Xenopus animal caps |
| Q34722748 | Activating mutations in protein tyrosine phosphatase Ptpn11 (Shp2) enhance reactive oxygen species production that contributes to myeloproliferative disorder |
| Q28613911 | Amplification of B cell antigen receptor signaling by a Syk/ITAM positive feedback loop |
| Q101051254 | An allosteric interaction controls the activation mechanism of SHP2 tyrosine phosphatase |
| Q42977534 | Analysis of the redox regulation of protein tyrosine phosphatase superfamily members utilizing a cysteinyl-labeling assay |
| Q35072229 | B cell inhibitory receptors and autoimmunity. |
| Q39110198 | Cell signaling as a cognitive process. |
| Q28609054 | Cloning of p97/Gab2, the major SHP2-binding protein in hematopoietic cells, reveals a novel pathway for cytokine-induced gene activation |
| Q34180660 | Combinatorial control of the specificity of protein tyrosine phosphatases |
| Q90092671 | Connecting the dots between SHP2 and glutamate receptors |
| Q55517431 | Co‐occurrence of hypertrophic cardiomyopathy and juvenile myelomonocytic leukemia in a neonate with Noonan syndrome, leading to premature death. |
| Q35973795 | Critical role of Src and SHP-2 in sst2 somatostatin receptor-mediated activation of SHP-1 and inhibition of cell proliferation |
| Q27667430 | Crystal structure of human protein tyrosine phosphatase SHP-1 in the open conformation |
| Q27640158 | Crystal structure of human protein-tyrosine phosphatase SHP-1 |
| Q33898986 | Cytoplasmic protein tyrosine phosphatases SHP-1 and SHP-2: regulators of B cell signal transduction. |
| Q37287463 | Deletion of SHP-2 in mesenchymal stem cells causes growth retardation, limb and chest deformity, and calvarial defects in mice |
| Q33979110 | Diverse driving forces underlie the invariant occurrence of the T42A, E139D, I282V and T468M SHP2 amino acid substitutions causing Noonan and LEOPARD syndromes |
| Q33799950 | Down-regulation of protein-tyrosine phosphatases activates an immune receptor in the absence of its translocation into lipid rafts |
| Q46863352 | Effects of a leukemia-associated gain-of-function mutation of SHP-2 phosphatase on interleukin-3 signaling |
| Q28215310 | Function and molecular modeling of the interaction between human interleukin 6 and its HNK-1 oligosaccharide ligands |
| Q35847802 | Functional analysis of leukemia-associated PTPN11 mutations in primary hematopoietic cells |
| Q52646137 | Gain-of-function mutations in the gene encoding the tyrosine phosphatase SHP2 induce hydrocephalus in a catalytically dependent manner. |
| Q41899097 | Grb2 controls phosphorylation of FGFR2 by inhibiting receptor kinase and Shp2 phosphatase activity |
| Q91593088 | HLA-F on Autologous HIV-Infected Cells Activates Primary NK Cells Expressing the Activating Killer Immunoglobulin-Like Receptor KIR3DS1 |
| Q35007083 | Hydrogen peroxide as second messenger in lymphocyte activation |
| Q34155125 | Identification of cryptotanshinone as an inhibitor of oncogenic protein tyrosine phosphatase SHP2 (PTPN11). |
| Q37104928 | Identification of small molecular weight inhibitors of Src homology 2 domain-containing tyrosine phosphatase 2 (SHP-2) via in silico database screening combined with experimental assay |
| Q33540512 | Immune signalling: SHP-2 docks at multiple ports |
| Q37150984 | Induction of a tumor-associated activating mutation in protein tyrosine phosphatase Ptpn11 (Shp2) enhances mitochondrial metabolism, leading to oxidative stress and senescence |
| Q36937153 | Inflammation and autoimmunity caused by a SHP1 mutation depend on IL-1, MyD88, and a microbial trigger |
| Q36951816 | Inhibition of SHP2 ameliorates the pathogenesis of systemic lupus erythematosus. |
| Q99634967 | Interaction of the Hippo Pathway and Phosphatases in Tumorigenesis |
| Q24294717 | Interaction of the tyrosine phosphatase SHP-2 with Gab2 regulates Rho-dependent activation of the c-fos serum response element by interleukin-2 |
| Q34467850 | Intracellular signaling by the killer immunoglobulin-like receptors and Ly49. |
| Q46862466 | Lethal proliferation of erythroid precursors in a neonate with a germline PTPN11 mutation |
| Q37176577 | Leukemogenic Ptpn11 causes fatal myeloproliferative disorder via cell-autonomous effects on multiple stages of hematopoiesis |
| Q58097742 | Mechanism of activating mutations and allosteric drug inhibition of the phosphatase SHP2 |
| Q28587122 | Megakaryocyte-specific deletion of the protein-tyrosine phosphatases Shp1 and Shp2 causes abnormal megakaryocyte development, platelet production, and function |
| Q28592055 | Mice lacking the ITIM-containing receptor G6b-B exhibit macrothrombocytopenia and aberrant platelet function |
| Q39328853 | Model-driven experimental analysis of the function of SHP-2 in IL-6-induced Jak/STAT signaling. |
| Q27684353 | Molecular Basis of Gain-of-Function LEOPARD Syndrome-Associated SHP2 Mutations |
| Q85544412 | Molecular mechanism of SHP2 activation by PD-1 stimulation |
| Q38248429 | Molecular pathogenesis of atypical CML, CMML and MDS/MPN-unclassifiable. |
| Q35014319 | Molecular recognition by SH2 domains |
| Q28594140 | Mouse model of Noonan syndrome reveals cell type- and gene dosage-dependent effects of Ptpn11 mutation |
| Q35685296 | Mutated Ptpn11 alters leukemic stem cell frequency and reduces the sensitivity of acute myeloid leukemia cells to Mcl1 inhibition |
| Q28608965 | New role for Shc in activation of the phosphatidylinositol 3-kinase/Akt pathway |
| Q35237519 | Non-lineage/stage-restricted effects of a gain-of-function mutation in tyrosine phosphatase Ptpn11 (Shp2) on malignant transformation of hematopoietic cells |
| Q40587895 | Noonan syndrome-associated SHP2/PTPN11 mutants cause EGF-dependent prolonged GAB1 binding and sustained ERK2/MAPK1 activation |
| Q34295050 | Oligomeric antigen receptors: a new view on signaling for the selection of lymphocytes |
| Q34347206 | PD-1 inhibits T-cell receptor induced phosphorylation of the ZAP70/CD3zeta signalosome and downstream signaling to PKCtheta |
| Q28288812 | PTPN11 (Shp2) mutations in LEOPARD syndrome have dominant negative, not activating, effects |
| Q36199863 | PTPs versus PTKs: the redox side of the coin |
| Q30278754 | Paraspinal neurofibromas and hypertrophic neuropathy in Noonan syndrome with multiple lentigines |
| Q37728541 | Phosphatase regulation of intercellular junctions |
| Q37102143 | Phosphatase-defective LEOPARD syndrome mutations in PTPN11 gene have gain-of-function effects during Drosophila development |
| Q42591567 | Phosphatase-dependent and -independent functions of Shp2 in neural crest cells underlie LEOPARD syndrome pathogenesis |
| Q38327588 | Phosphatidylinositol phosphate kinase type Igamma directly associates with and regulates Shp-1 tyrosine phosphatase. |
| Q44283243 | Platelet-endothelial cell adhesion molecule-1 modulates endothelial migration through its immunoreceptor tyrosine-based inhibitory motif |
| Q36603867 | Preferential oxidation of the second phosphatase domain of receptor-like PTP-alpha revealed by an antibody against oxidized protein tyrosine phosphatases |
| Q35101627 | Protein Tyrosine Phosphatase SHP-2 (PTPN11) in Hematopoiesis and Leukemogenesis |
| Q48329853 | Protein phosphatase 1γ isoforms linked interactions in the brain |
| Q53415824 | Protein tyrosine phosphatase epsilon increases the risk of mammary hyperplasia and mammary tumors in transgenic mice. |
| Q28646447 | Protein tyrosine phosphatases in the JAK/STAT pathway |
| Q53852755 | Protein tyrosine phosphatases: their role in insulin action and potential as drug targets. |
| Q50033709 | Proteinaceous Regulators and Inhibitors of Protein Tyrosine Phosphatases. |
| Q34627120 | Rapamycin reverses hypertrophic cardiomyopathy in a mouse model of LEOPARD syndrome-associated PTPN11 mutation. |
| Q33630136 | Reactive oxygen species play a critical role in collagen-induced platelet activation via SHP-2 oxidation |
| Q39674852 | Receptor-specific regulation of phosphatidylinositol 3'-kinase activation by the protein tyrosine phosphatase Shp2. |
| Q80691530 | Regulation of ACh receptor clustering by the tyrosine phosphatase Shp2 |
| Q40532735 | Regulation of SHP-1 tyrosine phosphatase in human platelets by serine phosphorylation at its C terminus |
| Q34262292 | Regulation of hematopoietic cell function by inhibitory immunoglobulin G receptors and their inositol lipid phosphatase effectors. |
| Q46804787 | Regulation of the catalytic activity of PTP1B: roles for cell adhesion, tyrosine residue 66, and proline residues 309 and 310. |
| Q48103763 | Regulatory Mechanisms and Novel Therapeutic Targeting Strategies for Protein Tyrosine Phosphatases. |
| Q38061128 | Research progress on the negative factors of corneal endothelial cells proliferation |
| Q89793206 | Resistance to allosteric SHP2 inhibition in FGFR-driven cancers through rapid feedback activation of FGFR |
| Q37438081 | SHP-2 expression negatively regulates NK cell function |
| Q34211722 | SHP-2 phosphatase activity is required for PECAM-1-dependent cell motility |
| Q40550696 | SHP-2 positively regulates myogenesis by coupling to the Rho GTPase signaling pathway |
| Q37186707 | SHP-2 tyrosine phosphatase in human diseases. |
| Q34290934 | SHP2 Mediates the Localized Activation of Fyn Downstream of the α6β4 Integrin To Promote Carcinoma Invasion |
| Q28211408 | SHP2 and SOCS3 contribute to Tyr-759-dependent attenuation of interleukin-6 signaling through gp130 |
| Q33292562 | SHP2 binds catalase and acquires a hydrogen peroxide-resistant phosphatase activity via integrin-signaling |
| Q46361900 | SHP2 is required for BCR-ABL1-induced hematologic neoplasia. |
| Q27700205 | Selective inhibitors of the protein tyrosine phosphatase SHP2 block cellular motility and growth of cancer cells in vitro and in vivo |
| Q36574874 | Shp2 Associates with and Enhances Nephrin Tyrosine Phosphorylation and Is Necessary for Foot Process Spreading in Mouse Models of Podocyte Injury. |
| Q36611001 | Signalling platforms that modulate the inflammatory response: new targets for drug development |
| Q93239307 | Small Molecule Inhibitor that Stabilizes the Autoinhibited Conformation of the Oncogenic Tyrosine Phosphatase SHP2 |
| Q40653225 | Src Homology Region 2-Containing Protein Tyrosine Phosphatase-2 (SHP-2) Can Play a Direct Role in the Inhibitory Function of Killer Cell Ig-Like Receptors in Human NK Cells |
| Q41432541 | Sticking It to Cancer with Molecular Glue for SHP2 |
| Q33556868 | Structural insights into Noonan/LEOPARD syndrome-related mutants of protein-tyrosine phosphatase SHP2 (PTPN11) |
| Q42716640 | Structural mechanism associated with domain opening in gain-of-function mutations in SHP2 phosphatase. |
| Q28610389 | Structure and function of major histocompatibility complex (MHC) class I specific receptors expressed on human natural killer (NK) cells |
| Q35781235 | Structure-based kinetic models of modular signaling protein function: focus on Shp2. |
| Q34299378 | Structure-energy-based predictions and network modelling of RASopathy and cancer missense mutations |
| Q42371502 | Targeting SHP-1-STAT3 signaling: A promising therapeutic approach for the treatment of cholangiocarcinoma |
| Q35001128 | Targeting a cryptic allosteric site for selective inhibition of the oncogenic protein tyrosine phosphatase Shp2 |
| Q37161507 | Targeting protein tyrosine phosphatase SHP2 for the treatment of PTPN11-associated malignancies |
| Q28182148 | The 'Shp'ing news: SH2 domain-containing tyrosine phosphatases in cell signaling |
| Q59790569 | The Allosteric Site on SHP2's Protein Tyrosine Phosphatase Domain is Targetable with Druglike Small Molecules |
| Q33940458 | The Gab1 docking protein links the b cell antigen receptor to the phosphatidylinositol 3-kinase/Akt signaling pathway and to the SHP2 tyrosine phosphatase. |
| Q24292713 | The major vault protein is a novel substrate for the tyrosine phosphatase SHP-2 and scaffold protein in epidermal growth factor signaling |
| Q22009405 | The myeloid-specific sialic acid-binding receptor, CD33, associates with the protein-tyrosine phosphatases, SHP-1 and SHP-2 |
| Q92626439 | The prognostic significance of SHP2 and its binding protein Hook1 in non-small cell lung cancer |
| Q35118478 | The role of the protein tyrosine phosphatase SHP2 in cardiac development and disease. |
| Q28144584 | The transmembranal and cytoplasmic forms of protein tyrosine phosphatase epsilon physically associate with the adaptor molecule Grb2 |
| Q33605698 | The tyrosine phosphatase SHP-2 is required for sustained activation of extracellular signal-regulated kinase and epithelial morphogenesis downstream from the met receptor tyrosine kinase |
| Q39583606 | The tyrosine phosphatase SHP2 associates with CUB domain-containing protein-1 (CDCP1), regulating its expression at the cell surface in a phosphorylation-dependent manner |
| Q37732956 | The tyrosine phosphatase Shp2 in development and cancer |
| Q28118868 | Tyrosyl phosphorylation of Shp2 is required for normal ERK activation in response to some, but not all, growth factors |
| Q35849700 | Uncoupling of T-cell effector functions by inhibitory killer immunoglobulin-like receptors. |
| Q35661770 | Vav1 dephosphorylation by the tyrosine phosphatase SHP-1 as a mechanism for inhibition of cellular cytotoxicity |
Search more.